ITRM960364A0 - Agente attivo terapeutico per il trattamento di malattie degenerative neuronali. - Google Patents

Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.

Info

Publication number
ITRM960364A0
ITRM960364A0 ITRM960364A ITRM960364A ITRM960364A0 IT RM960364 A0 ITRM960364 A0 IT RM960364A0 IT RM960364 A ITRM960364 A IT RM960364A IT RM960364 A ITRM960364 A IT RM960364A IT RM960364 A0 ITRM960364 A0 IT RM960364A0
Authority
IT
Italy
Prior art keywords
treatment
therapeutic agent
degenerative diseases
active therapeutic
neuronal degenerative
Prior art date
Application number
ITRM960364A
Other languages
English (en)
Inventor
Vincenzo Politi
Mario Materazzi
Original Assignee
Polifarma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma Spa filed Critical Polifarma Spa
Publication of ITRM960364A0 publication Critical patent/ITRM960364A0/it
Priority to IT96RM000364A priority Critical patent/IT1290781B1/it
Priority to PCT/IT1997/000117 priority patent/WO1997045127A1/en
Priority to AU30468/97A priority patent/AU3046897A/en
Priority to CA002255748A priority patent/CA2255748C/en
Priority to BR9709379-3A priority patent/BR9709379A/pt
Priority to HU0000124A priority patent/HUP0000124A3/hu
Priority to EP97925266A priority patent/EP0914131A1/en
Priority to JP54197097A priority patent/JP3725172B2/ja
Publication of ITRM960364A1 publication Critical patent/ITRM960364A1/it
Application granted granted Critical
Publication of IT1290781B1 publication Critical patent/IT1290781B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT96RM000364A 1996-05-28 1996-05-28 Agente attivo terapeutico per il trattamento di malattie degenerative neuronali. IT1290781B1 (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT96RM000364A IT1290781B1 (it) 1996-05-28 1996-05-28 Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
BR9709379-3A BR9709379A (pt) 1996-05-28 1997-05-23 Uso de uridina, e, composição para o tratamento de distúrbios do sistema nervoso devido à degeneração seletiva de células neuroniais ou gliais em mamìferos.
AU30468/97A AU3046897A (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
CA002255748A CA2255748C (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
PCT/IT1997/000117 WO1997045127A1 (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
HU0000124A HUP0000124A3 (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
EP97925266A EP0914131A1 (en) 1996-05-28 1997-05-23 Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
JP54197097A JP3725172B2 (ja) 1996-05-28 1997-05-23 ウリジンからなる神経変性疾患の処置に活性な治療剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96RM000364A IT1290781B1 (it) 1996-05-28 1996-05-28 Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US1854396P 1996-05-29 1996-05-29

Publications (3)

Publication Number Publication Date
ITRM960364A0 true ITRM960364A0 (it) 1996-05-28
ITRM960364A1 ITRM960364A1 (it) 1997-11-28
IT1290781B1 IT1290781B1 (it) 1998-12-10

Family

ID=26332100

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96RM000364A IT1290781B1 (it) 1996-05-28 1996-05-28 Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.

Country Status (4)

Country Link
EP (1) EP0914131A1 (it)
AU (1) AU3046897A (it)
IT (1) IT1290781B1 (it)
WO (1) WO1997045127A1 (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
DK1870103T3 (da) * 1998-07-31 2010-01-11 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
NZ528634A (en) * 2001-04-30 2005-04-29 Trommsdorff Gmbh & Co Pharmaceutically active uridine esters
US6767202B2 (en) 2001-12-18 2004-07-27 3M Innovative Properties Company Tooling with helical coils for structured surface articles
EP1750509A4 (en) * 2004-05-13 2010-03-24 Massachusetts Inst Technology EFFECTS OF URIDINE ON DOPAMINE RELIEF
AU2005285090A1 (en) * 2004-09-15 2006-03-23 Massachusetts Institute Of Technology Compositions containing uridine, and methods utilizing same
EP1974732A4 (en) 2005-11-24 2010-08-11 Univ Hokkaido Nat Univ Corp THERAPEUTIC AGENT AGAINST NEURODE GENERATIVE DISEASES
BRPI0817387A2 (pt) 2007-11-02 2015-09-08 Massachusetts Inst Technology métodos de conformidade de suplementação dietária de uridina e uso dos mesmos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1178044B (it) * 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
IT1241984B (it) * 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
JPH05304951A (ja) * 1992-04-06 1993-11-19 N T Sci:Kk 初期胚及び胚性幹細胞の培養液

Also Published As

Publication number Publication date
EP0914131A1 (en) 1999-05-12
AU3046897A (en) 1998-01-05
ITRM960364A1 (it) 1997-11-28
IT1290781B1 (it) 1998-12-10
WO1997045127A1 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
FI963696A7 (fi) Geeli ihosairauksien hoitoon ja ihon desinfiointiin
ITTO950104A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
ITTO950099A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
FI20000720L (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
NO20000688D0 (no) Anvendelse av lokalt avleverte metallioner for behandling av periodontal sykdom
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
ID23528A (id) Pengobatan terapeutik untuk gangguan kulit
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer's disease.
EP0744176A3 (en) Methods for inhibiting bone loss
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
NO982562D0 (no) Sammensetning for behandling av smerte
FI952953L (fi) Aineita metabolisten luustosairauksien hoitamiseen
IT240104Y1 (it) Dispositivo per il trattamento del corpo umano.
FI950649A7 (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet
GB9615710D0 (en) Pharmaceutical preparations for the treatment of sarcocystosis
GC0000176A (en) Pharmaceutical combination preparations for the treatment of cardiac disorders
RU97111440A (ru) Препарат для лечения отморожений
ITBO940254A0 (it) Metodo per il miglioramento di alcune funzionalita' del corpo umano.
FR2786099B1 (fr) Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline

Legal Events

Date Code Title Description
0001 Granted